NO327042B1 - Anvendelse av en effektiv mengde av NDISACC-(4-(4-klorfenyl)benzyl)A82846B for fremstilling av et medikament for behandling av en infeksjonssykdom. - Google Patents

Anvendelse av en effektiv mengde av NDISACC-(4-(4-klorfenyl)benzyl)A82846B for fremstilling av et medikament for behandling av en infeksjonssykdom. Download PDF

Info

Publication number
NO327042B1
NO327042B1 NO20000851A NO20000851A NO327042B1 NO 327042 B1 NO327042 B1 NO 327042B1 NO 20000851 A NO20000851 A NO 20000851A NO 20000851 A NO20000851 A NO 20000851A NO 327042 B1 NO327042 B1 NO 327042B1
Authority
NO
Norway
Prior art keywords
strain
chlorophenyl
benzyl
medicament
treatment
Prior art date
Application number
NO20000851A
Other languages
English (en)
Norwegian (no)
Other versions
NO20000851L (no
NO20000851D0 (no
Inventor
Thalia Ioanna Nicas
David Albert Preston
Michael Lee Zeckel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20000851L publication Critical patent/NO20000851L/no
Publication of NO20000851D0 publication Critical patent/NO20000851D0/no
Publication of NO327042B1 publication Critical patent/NO327042B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20000851A 1997-08-22 2000-02-21 Anvendelse av en effektiv mengde av NDISACC-(4-(4-klorfenyl)benzyl)A82846B for fremstilling av et medikament for behandling av en infeksjonssykdom. NO327042B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5671297P 1997-08-22 1997-08-22
PCT/US1998/017138 WO1999010006A1 (en) 1997-08-22 1998-08-18 Therapy for staphylococcus aureus

Publications (3)

Publication Number Publication Date
NO20000851L NO20000851L (no) 2000-02-21
NO20000851D0 NO20000851D0 (no) 2000-02-21
NO327042B1 true NO327042B1 (no) 2009-04-06

Family

ID=22006150

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000851A NO327042B1 (no) 1997-08-22 2000-02-21 Anvendelse av en effektiv mengde av NDISACC-(4-(4-klorfenyl)benzyl)A82846B for fremstilling av et medikament for behandling av en infeksjonssykdom.

Country Status (23)

Country Link
US (1) US5994297A (ru)
EP (1) EP0897725B1 (ru)
JP (1) JP2001513573A (ru)
KR (1) KR100589548B1 (ru)
CN (1) CN1276728A (ru)
AT (1) ATE278413T1 (ru)
AU (1) AU747418B2 (ru)
BR (1) BR9811917A (ru)
CA (1) CA2301589A1 (ru)
CZ (1) CZ299098B6 (ru)
DE (1) DE69826795T2 (ru)
DK (1) DK0897725T3 (ru)
EA (1) EA002602B1 (ru)
ES (1) ES2229454T3 (ru)
HU (1) HU226593B1 (ru)
ID (1) ID24908A (ru)
IL (2) IL134597A0 (ru)
NO (1) NO327042B1 (ru)
NZ (1) NZ502762A (ru)
PT (1) PT897725E (ru)
TR (1) TR200000475T2 (ru)
UA (1) UA59410C2 (ru)
WO (1) WO1999010006A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736860C (en) * 2008-08-30 2020-04-28 Targanta Therapeutics Corp. Methods of treatment using single doses of oritavancin
CN101928331B (zh) * 2009-06-26 2014-05-28 上海来益生物药物研究开发中心有限责任公司 一种化合物及其应用
MX2015011760A (es) 2013-03-15 2016-06-10 Melinta Therapeutics Inc Metodos para tratar infecciones en pacientes obesos y con sobrepeso usando antibioticos.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU703106B2 (en) * 1994-01-28 1999-03-18 Eli Lilly And Company Glycopeptide antibiotic derivatives

Also Published As

Publication number Publication date
ATE278413T1 (de) 2004-10-15
EA002602B1 (ru) 2002-06-27
WO1999010006A1 (en) 1999-03-04
EP0897725A2 (en) 1999-02-24
DE69826795T2 (de) 2005-10-06
PT897725E (pt) 2004-12-31
AU8913798A (en) 1999-03-16
EP0897725B1 (en) 2004-10-06
NO20000851L (no) 2000-02-21
NO20000851D0 (no) 2000-02-21
IL134597A (en) 2007-09-20
BR9811917A (pt) 2000-08-15
ES2229454T3 (es) 2005-04-16
ID24908A (id) 2000-08-31
KR20010023108A (ko) 2001-03-26
DE69826795D1 (de) 2004-11-11
CZ299098B6 (cs) 2008-04-23
EA200000250A1 (ru) 2000-08-28
NZ502762A (en) 2001-10-26
HUP0002920A3 (en) 2001-12-28
DK0897725T3 (da) 2004-12-13
KR100589548B1 (ko) 2006-06-15
CA2301589A1 (en) 1999-03-04
AU747418B2 (en) 2002-05-16
US5994297A (en) 1999-11-30
CZ2000619A3 (en) 2001-05-16
HUP0002920A2 (hu) 2001-01-29
HU226593B1 (en) 2009-04-28
JP2001513573A (ja) 2001-09-04
CN1276728A (zh) 2000-12-13
EP0897725A3 (en) 2000-02-09
IL134597A0 (en) 2001-04-30
TR200000475T2 (tr) 2000-08-21
UA59410C2 (ru) 2003-09-15

Similar Documents

Publication Publication Date Title
Candiani et al. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic
Poutsiaka et al. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients
Freeman et al. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci
Castanheira et al. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006)
NO327042B1 (no) Anvendelse av en effektiv mengde av NDISACC-(4-(4-klorfenyl)benzyl)A82846B for fremstilling av et medikament for behandling av en infeksjonssykdom.
CN111920805A (zh) 富马酸氯马斯汀在抗耐甲氧西林金黄葡萄球菌制剂中的应用
JP2629166B2 (ja) メチシリン耐性黄色ブドウ球菌に有効な抗菌剤
EA022060B1 (ru) Соединение для лечения инфекционных заболеваний, соответствующий способ и фармацевтическая композиция, содержащая указанное соединение
Al-Nawas et al. Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus
CN110302201B (zh) 苯乙烯喹啉衍生物在制备抗耐药菌药物中的应用和抗耐药菌药物
Houston et al. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin
Zinkernagel et al. Rapidly destructive Staphylococcus epidermidis endocarditis
MXPA00001841A (en) Therapy for staphylococcus aureus
KR20220074300A (ko) 황색포도상구균 또는 장구균에 대한 항균용 조성물
RU2754610C1 (ru) Препарат для лечения заболеваний, вызванных бактериями
CN114432428B (zh) PGLa提高细菌对抗生素的敏感性和延缓细菌耐药性产生的应用
JP6749617B2 (ja) 抗菌性合剤の探索方法
US20190388437A1 (en) Compositions and methods for treating bone and joint infections
Voorn et al. Paradoxical dose effect of continuously administered cloxacillin in treatment of tolerant Staphylococcus aureus endocarditis in rats
CN110801455A (zh) 用于治疗mrsa的药物组合物及其应用
PL190418B1 (pl) Zastosowanie NDISACC-(4-(4-chlorofenylo)benzylo)-A82846B lub jego soli
JPS59116217A (ja) マイコプラズマ感染症用薬
CN115645414A (zh) 抗菌药物组合物及其应用
CN116139143A (zh) 天然药物在制备抗革兰氏阳性菌药物中的应用
Lemmen et al. Mic and serum bactericidal activity of clindamycin against methicillin-resistant and-sensitive staphylococci

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees